M
Mark E. Anderson
Researcher at Johns Hopkins University School of Medicine
Publications - 307
Citations - 20458
Mark E. Anderson is an academic researcher from Johns Hopkins University School of Medicine. The author has contributed to research in topics: Ca2+/calmodulin-dependent protein kinase & Medicine. The author has an hindex of 72, co-authored 252 publications receiving 17510 citations. Previous affiliations of Mark E. Anderson include Vanderbilt University & University of Colorado Denver.
Papers
More filters
Journal ArticleDOI
Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Transmission Dynamics and Immune Responses in a Household of Vaccinated Persons
Jamin Liu,Matthew T. Laurie,Luis Rubio,Sara E. Vazquez,Sara Sunshine,A. Mitchell,Matthias Shifferaw Hapte-Selassie,Sabrina A Mann,Genay Pilarowski,Douglas Black,Carina Marquez,Susana Rojas,Michail S. Lionakis,Maya L. Petersen,Jeffrey D. Whitman,Vivek Jain,Mark E. Anderson,Diane V. Havlir,Joseph L. DeRisi +18 more
TL;DR: An in-depth characterization of transmission and immunity among vaccinated individuals in a household is presented, revealing complex dynamics and unappreciated comorbidities, including autoimmunity to type 1 interferon in the presumptive index case.
Journal ArticleDOI
TCT-98 Percutaneous Right Ventricular Support with Impella RP in Severe Right Ventricular Failure: insights from Impella RP clinical studies
TL;DR: Right Ventricular Failure post myocardial infarction, post cardiotomy or post LVAD implantation increases morbidity and mortality and contributes to prolonged hospital length of stay and higher costs of care.
Proceedings ArticleDOI
CaMKII As A Pro-Asthmatic Signal
Philip N. Sanders,Patrick J. Hayden,Long-Sheng Song,Joel N. Kline,Peter J. Mohler,Isabella M. Grumbach,Mark E. Anderson +6 more
Group of the National Heart, Lung, and Blood Institute Research Priorities in Hypertrophic Cardiomyopathy : Report of a Working
Marvin A. Konstam,Barry J. Maron,Steve R. Ommen,Michael Regnier,W. H. Wilson Tang,Rong Tian,Thomas P. Cappola,Raghu Kalluri,Martin M. LeWinter,Martin S. Maron,Bishow B. Adhikari,Mark E. Anderson,Robin Boineau,Barry J. Byrne,Thomas Force,Robert O. Bonow,Steven R. Houser,R. John +17 more
Journal ArticleDOI
Phase I study of anti-epidermal growth factor receptor antibody-drug conjugate serclutamab talirine: Safety, pharmacokinetics, and antitumor activity in advanced glioblastoma
Benedito A. Carneiro,Kyriakos P. Papadopoulos,John G. Strickler,Andrew B. Lassman,Saiama N. Waqar,Young Kwang Chae,Jyoti D. Patel,Einat Shacham-Shmueli,Karen Kelly,Mustafa Khasraw,Christine Bestvina,Ryan Merrell,Kevin Huang,Harisha Atluri,Peter Ansell,Rachel W. Li,Janet Yikai Jin,Mark E. Anderson,Edward B. Reilly,G. Morrison-Thiele,Kalpesh N. Patel,Randy Robinson,Martha R Neagu Aristide,Hui K Gan +23 more
TL;DR: Serclutamab talirine (Ser-T) is an antibody-drug conjugate consisting of an antibody (AM-1-ABT-806) directed against activated epidermal growth factor receptor (EGFR) and a pyrrolobenzodiazepine dimer as mentioned in this paper .